The CXO board plunged as Pharming was included in the “unverified list” of the US Department of Commerce


CDMO Bio-tech and Bio-Tech (Shanghai) were among 33 Chinese companies added to the updated “Unverified List” (UVL) issued by the US Bureau of Industry and Security (BIS) of the Us Department of Commerce yesterday.Affected by the bad news, Hong Kong shares pharmaceutical fell 27%, pharmaceutical fell 22%, Pharmaron fell 10%, Tiger Pharmaceutical fell 9%, CXO board plummeted., biological medicine out in response to this morning said: “without checking list” is not better known in the United States “entity list” or “blacklist”, medicine Ming biological bioreactor has been imported some hardware controller and hollow fiber filter, the controller by the U.S. export controls, but in the past 10 years has been approved by the us department of commerce.”We comply with all US export control regulations.We will not re-export or resell these items to any other entity.The U.S. Department of Commerce has a routine process to verify these for proper use in the field (i.e. for personal use, not for resale).This process has not been completed in the past two years due to the COVID-19 pandemic.This has no impact on our business or continued service to our global partners.Since facilities in Shanghai and Wuxi do not need such equipment after construction, the impact on our imports is very small.”Specifically, the BIS blacklist includes the list of rejected persons, the list of unverified persons, the list of entities, and the list of military end-users.The export, re-export, or domestic transfer of any U.S. items to individuals and entities on the Entity List requires a special license from BIS, with no license exception applicable.Unlike the entity list, the unverified list is less restrictive, with no permitted exceptions and a “UVL declaration” required for the export, re-export, or transfer of U.S. origin items to purchasers, intermediate consignees, final consignees, or end users listed on the UVL list.The US unverified list is mainly for parties to which BIS has been unable to confirm the end-use of items in its previous transactions.The main scope of impact includes bioreactors and other related containers, chemicals that have the potential to produce biological and chemical weapons.Reasons for inclusion may include BIS inability to complete end-use verification to verify the “good faith” of the entity, or failure to verify the “good faith” of the entity when the end-use verification is carried out, including whether it is cooperating with the investigation, whether it is contacting the entity, etc., and the pandemic may interrupt the investigation and make it impossible to verify the “good faith”.UVL companies can take steps to be removed from the list, which can take months.According to the revenue structure of Yao Ming Biobiao for 21 years, the revenue of the United States accounted for nearly 50%, while that of China accounted for only 26.35%, which is extremely dependent on overseas markets.Just yesterday, The company just disclosed the performance of 21 years, the company announced that the annual profit of 2021 is expected to increase by more than 105% year-on-year, and the profit attributable to equity shareholders is expected to increase by more than 98% year-on-year.Pharmatobics continued high performance growth, further refresh the previous earnings guidance.According to the performance forecast, the annual profit in 2021 is expected to be more than 3.471 billion yuan, and the profit in the second half of the year is expected to be more than 1.588 billion yuan, with a year-on-year growth of more than 65%.The annual profit attributable to equity shareholders in 2021 is expected to be more than 3.344 billion yuan, and the profit attributable to equity shareholders in the second half of 2021 is expected to be more than 1.502 billion yuan, with a year-on-year growth of more than 58%.But at present the overall mood of the biomedical industry is very pessimistic, any wind can cause a collective fall, but turn a blind eye to the good.According to the overall goal of the 14th Five-Year Plan for the development of the pharmaceutical industry, economies of scale in the pharmaceutical industry will grow steadily by 2025.Keep the annual growth rate of operating revenue and total profits above 8%, and increase the proportion of added value in all industries to around 5%.The concentration of leading enterprises in the industry has further improved.Results of innovation-driven transformation were evident.The r&d investment of the whole industry will increase by more than 10% annually.By 2025, new sales of innovative products will account for a further increase in the industry’s operating revenue.In addition, the US Department of Commerce added Pharming bio to the unverified list, reminding the biomedical industry to speed up the process of localization of key products to avoid bottlenecks.In recent years, domestic culture media, reactors, purification equipment, membrane materials, analytical instruments and other rapid progress, the key reagents, consumables, equipment, instrument replacement has been the general trend, novizan, East Furong, Chutian Technology, Kingsrui, micro technology and a number of upstream companies are expected to continue to benefit.

Leave a Reply

Your email address will not be published.